AU2014358677A1 - Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 - Google Patents

Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 Download PDF

Info

Publication number
AU2014358677A1
AU2014358677A1 AU2014358677A AU2014358677A AU2014358677A1 AU 2014358677 A1 AU2014358677 A1 AU 2014358677A1 AU 2014358677 A AU2014358677 A AU 2014358677A AU 2014358677 A AU2014358677 A AU 2014358677A AU 2014358677 A1 AU2014358677 A1 AU 2014358677A1
Authority
AU
Australia
Prior art keywords
isolated peptide
pharmaceutical composition
seq
peptide
denoted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014358677A
Other languages
English (en)
Inventor
Gila Arad
Raymond Kaempfer
Anat Shirvan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATOX BIO Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
ATOX BIO Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ATOX BIO Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical ATOX BIO Ltd
Publication of AU2014358677A1 publication Critical patent/AU2014358677A1/en
Priority to AU2017261479A priority Critical patent/AU2017261479B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
AU2014358677A 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 Abandoned AU2014358677A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017261479A AU2017261479B2 (en) 2013-12-06 2017-11-14 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361912631P 2013-12-06 2013-12-06
US61/912,631 2013-12-06
US201461924869P 2014-01-08 2014-01-08
US61/924,869 2014-01-08
PCT/IL2014/051067 WO2015083173A1 (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017261479A Division AU2017261479B2 (en) 2013-12-06 2017-11-14 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28

Publications (1)

Publication Number Publication Date
AU2014358677A1 true AU2014358677A1 (en) 2016-06-02

Family

ID=52396781

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014358677A Abandoned AU2014358677A1 (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28
AU2017261479A Ceased AU2017261479B2 (en) 2013-12-06 2017-11-14 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017261479A Ceased AU2017261479B2 (en) 2013-12-06 2017-11-14 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28

Country Status (7)

Country Link
US (2) US9963497B2 (cg-RX-API-DMAC10.html)
EP (1) EP3077415B1 (cg-RX-API-DMAC10.html)
JP (1) JP6757667B2 (cg-RX-API-DMAC10.html)
AU (2) AU2014358677A1 (cg-RX-API-DMAC10.html)
CA (1) CA2932150A1 (cg-RX-API-DMAC10.html)
SG (2) SG10201804750XA (cg-RX-API-DMAC10.html)
WO (1) WO2015083173A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201804750XA (en) * 2013-12-06 2018-07-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
US11304989B2 (en) 2017-10-06 2022-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Peptides for use in the treatment of viral infections
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CN111253469B (zh) * 2020-03-06 2021-09-07 暨南大学 一种自组装短肽及其在治疗痤疮方面的应用
EP4426715A1 (en) * 2021-11-02 2024-09-11 Enumita AS Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535672B2 (en) * 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
WO2004087754A1 (en) 2003-04-03 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
EP2804619B1 (en) 2012-01-16 2021-10-13 Atox Bio Ltd. Reltecimod for treatment of bacterial infections
SG10201804750XA (en) * 2013-12-06 2018-07-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Also Published As

Publication number Publication date
EP3077415B1 (en) 2020-02-12
SG11201604512XA (en) 2016-07-28
US20160289295A1 (en) 2016-10-06
JP2017501999A (ja) 2017-01-19
SG10201804750XA (en) 2018-07-30
US10280209B2 (en) 2019-05-07
WO2015083173A1 (en) 2015-06-11
AU2017261479B2 (en) 2019-05-02
CA2932150A1 (en) 2015-06-11
AU2017261479A1 (en) 2017-11-30
EP3077415A1 (en) 2016-10-12
US9963497B2 (en) 2018-05-08
US20180215804A1 (en) 2018-08-02
JP6757667B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
US10280209B2 (en) Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28
EP3551664B1 (en) Antibodies and polypeptides directed against cd127
KR20220048988A (ko) 대식세포 특이적 인게이저 조성물 및 이의 사용 방법
EP2680872B1 (en) Use of pif peptides for treating infections, atherosclerosis and peritonitis
KR20160020405A (ko) 약학적 조성물
RS67385B1 (sr) Antitela koja se vezuju za citrulinisani histon 2a i/ili 4
US11613565B2 (en) Isolated peptides derived from the B7 ligand dimer interface and uses thereof
CN113508129A (zh) 突变的白介素-34(il-34)多肽及其在治疗中的用途
EP4041283A1 (en) Il-2 chimeric proteins for immunosuppression
JP2023036860A (ja) 腫瘍浸潤ｔ細胞集団を生成する方法
KR102456666B1 (ko) ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer)
JP7778070B2 (ja) 免疫調節のための化合物
KR101913333B1 (ko) 신규 ctl 에피토프 4 연결 펩타이드
EP3749684A1 (en) Modified immunomodulatory peptide
US20230190865A1 (en) VIP Antagonists and Uses in Treating Cancer
CN116710114A (zh) Glp-1/glp-2双重激动剂的药物组合物
EP3126377B1 (en) An isolated donor mhc-derived peptide and uses thereof
CA3218327A1 (en) Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
JP6758022B2 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
KR20180132766A (ko) 신규한 ｔｓｌｐ 저해인자
EP4714969A1 (en) Compositions comprising soluble tigit and pd-1 - pd-l1 axis inhibitors and uses thereof
RU2851193C2 (ru) Мутантный полипептид интерлейкина-34 (IL-34) и его применение в терапии
JP7245844B2 (ja) 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
EP4082562A2 (en) Polypeptides comprising mutated forms of human vegf-a with rearrangements of disulfide bonds and compositions containing same
HK40103919A (en) Protease-activated polypeptides

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted